<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="± 3.22 μM was not prominent among the tested compounds," exact="lumefantrine" post="showed therapeutic promise due to high plasma and lung"/>
 <result pre="Further mode of action analysis revealed that arteannuin B and" exact="lumefantrine" post="acted at the post-entry step of SARS-CoV-2 infection. This"/>
 <result pre="and provides leading candidates for anti-SARS-CoV-2 drug research and development." exact="artemisinin" post="SARS-CoV-2 COVID-19 antiviral drug drug repurposing The COVID-19 pandemic"/>
 <result pre="a decades-old antimalarial drug with immune-modulation activities, and its derivative" exact="hydroxychloroquine" post="could efficiently inhibit SARS-CoV-2 in vitro.4,5 This raises an"/>
 <result pre="drugs derived from artemisinin.9−11 Arteannuin B and artemisinic acid are" exact="artemisinin" post="derivatives reported to have therapeutic efficacy against malaria in"/>
 <result pre="have reported the broad-spectrum antiviral potential of artemisinins. For example," exact="artesunate" post="effectively inhibits a wide range of DNA and RNA"/>
 <result pre="polyomavirus BK.14 Clinical trials focusing on the antiviral efficacy of" exact="artesunate" post="suggested that it shows promise for the treatment of"/>
 <result pre="most viral NP protein was inhibited when artesunate, dihydroartemisinin, and" exact="lumefantrine" post="were added at 25 μM, 25 μM, and 100"/>
 <result pre="were treated with 25 μM arteannuin B or 100 of" exact="lumefantrine" post="at different steps of infection (full-time, entry, and post-entry),"/>
 <result pre="when the drug was added at the post-entry step. Similarly," exact="lumefantrine" post="showed inhibitory effects when added during the full-time infection"/>
 <result pre="entry (Figure 4A,D,E). These data revealed that arteannuin B and" exact="lumefantrine" post="might function at a similar stage by interfering with"/>
 <result pre="treatment at different stages. (D) NP expression was visualized after" exact="lumefantrine" post="treatment at different stages. (E) NP expression was quantified"/>
 <result pre="(E) NP expression was quantified by Western blot assays after" exact="lumefantrine" post="treatment at different stages. Results are representative of n"/>
 <result pre="doses of 480 mg over 3 days, the EC50 of" exact="lumefantrine" post="was reached both in plasma and in the lungs."/>
 <result pre="and in the lungs. These results suggest the potential of" exact="lumefantrine" post="as a potential anti-SARS-CoV-2 agent. Figure 5 Predictive performance"/>
 <result pre="drug distribution of lumefantrine. (A) Simulated plasma concentration–time profile of" exact="lumefantrine" post="following six oral doses of 480 mg over 3"/>
 <result pre="95th percentiles of prediction. (B) Predicted lung concentration–time profile of" exact="lumefantrine" post="following six oral doses of 480 mg over 3"/>
 <result pre="dengue virus and HSV-1.23,24 Artesunate is a structural derivative of" exact="artemisinin" post="characterized by its broad-spectrum antiviral potential against DNA and"/>
 <result pre="potential of artemisinins against SARS-CoV-2 in vitro and discovered that" exact="artesunate" post="could inhibit SARS-CoV-2 replication in a dose-dependent manner. Arteannuin"/>
 <result pre="SARS-CoV-2 replication in a dose-dependent manner. Arteannuin B is another" exact="artemisinin" post="derivative that had an ideal EC50 value, suggesting its"/>
 <result pre="an important reference for estimating clinical efficacy. The Cmax of" exact="artesunate" post="was 42 μM following a single intravenous injection dose"/>
 <result pre="of 13.31 ± 1.24 μM (the in vivo metabolite of" exact="artesunate" post="was dihydroartemisinin) against SARS-CoV-2, indicating that artesunate is a"/>
 <result pre="vivo metabolite of artesunate was dihydroartemisinin) against SARS-CoV-2, indicating that" exact="artesunate" post="is a potential countermeasure against COVID-19.25 Coartem is a"/>
 <result pre="is a pharmaceutical compound preparation composed of artemether–lumefantrine (20 mg" exact="artemether" post="and 120 mg lumefantrine per tablet). The Cmax of"/>
 <result pre="preparation composed of artemether–lumefantrine (20 mg artemether and 120 mg" exact="lumefantrine" post="per tablet). The Cmax of artemether was found to"/>
 <result pre="artemether and 120 mg lumefantrine per tablet). The Cmax of" exact="artemether" post="was found to be low (0.28 μM); however, the"/>
 <result pre="found to be low (0.28 μM); however, the Cmax of" exact="lumefantrine" post="was much higher. Moreover, the plasma half-life of lumefantrine"/>
 <result pre="of lumefantrine was much higher. Moreover, the plasma half-life of" exact="lumefantrine" post="was determined to be 119 h, and the long"/>
 <result pre="the future optimization of artemisinins as anti-SARS-CoV-2 agents. Artemisinins, especially" exact="artesunate" post="and its active metabolite dihydroartemisinin, have been shown to"/>
 <result pre="the present and previous studies. Accumulating studies have suggested that" exact="artesunate" post="is likely to impair viral infection by modulating host"/>
 <result pre="host cell metabolic pathways. In particular, the anti-HCMV efficacy of" exact="artesunate" post="is associated with the PI3-K/Akt/p70S6K signaling pathway. Artesunate was"/>
 <result pre="of artemisinins against SARS-CoV-2 in vitro. Artesunate, arteannuin B, and" exact="lumefantrine" post="showed promise as anti-SARS-CoV-2 agents in vitro. Combined with"/>
 <result pre="safety and potential immunoregulatory activities of artemisinins, we believe that" exact="artemisinin" post="might represent a potential medical countermeasure against COVID-19. Methods"/>
 <result pre="0.05 was considered statistically significant. Materials Artemisinin (CAS No. 63968-64-9)," exact="artemether" post="(CAS No. 71963-77-4), artesunate (CAS No. 88495-63-0), dihydroartemisinin (CAS"/>
 <result pre="significant. Materials Artemisinin (CAS No. 63968-64-9), artemether (CAS No. 71963-77-4)," exact="artesunate" post="(CAS No. 88495-63-0), dihydroartemisinin (CAS No. 71939-50-9), artemisinic acid"/>
 <result pre="artemisinic acid (CAS No. 80286-58-4), arteether (CAS No. 75887-54-6), and" exact="lumefantrine" post="(CAS No. 82186-77-4) were purchased from Selleck. Arteannuin B"/>
 <result pre="YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG. (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="TanD. W. S.; WongF. W. S.; TranT. (2020) Anti-malarial drug," exact="artemisinin" post="and its derivatives for the treatment of respiratory diseases."/>
 <result pre="UzunT.; ToptasO. (2020) Artesunate: could be an alternative drug to" exact="chloroquine" post="in COVID-19 treatment?. Chin. Med.15, 5410.1186/s13020-020-00336-8.32514287 HoW. E.; PehH."/>
 <result pre="in Artemisia annua L. leading to enhanced antiplasmodial potency of" exact="artemisinin" post="via regulation of its metabolism. J. Ethnopharmacol.207, 86–91. 10.1016/j.jep.2017.06.025.28642094"/>
 <result pre="G.; StammingerT.; MarinJ. J.; MarschallM. (2008) The antiviral activities of" exact="artemisinin" post="and artesunate. Clin. Infect. Dis.47, 804–811. 10.1086/591195.18699744 RaffetinA.; BruneelF.;"/>
 <result pre="RaffetinA.; BruneelF.; RousselC.; ThellierM.; BuffetP.; CaumesE.; JaureguiberryS. (2018) Use of" exact="artesunate" post="in non-malarial indications. Med. Mal. Infect.48, 238–249. 10.1016/j.medmal.2018.01.004.29422423 ShapiraM."/>
 <result pre="SchnepfN. (2014) Stability and antiviral activity against human cytomegalovirus of" exact="artemisinin" post="derivatives. J. Antimicrob. Chemother.69, 34–40. 10.1093/jac/dkt346.24003183 HanY.; PhamH. T.;"/>
 <result pre="LefèvreG.; KernS. E. (2010) The effect of food consumption on" exact="lumefantrine" post="bioavailability in African children receiving artemether-lumefantrine crushed or dispersible"/>
 <result pre="GhavamiS.; LankaraniK. B. (2016) New use of an old drug:" exact="chloroquine" post="reduces viral and ALT levels in HCV non-responders (a"/>
 <result pre="HungN. C.; DavisT. M. (2002) The pharmacokinetic properties of intramuscular" exact="artesunate" post="and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br. J."/>
 <result pre="HauberI.; OlbrichA.; KronschnablM.; StammingerT.; HuangE. S. (2002) Antiviral activity of" exact="artesunate" post="towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol."/>
 <result pre="KalmerM.; BruggemanC. A.; VinkC.; StammingerT.; MarschallM. (2006) The anti-malaria drug" exact="artesunate" post="inhibits replication of cytomegalovirus in vitro and in vivo."/>
 <result pre="A.; VallejoM.; EfferthT.; AlvarezM.; MarinJ. J. (2006) Antiviral effect of" exact="artemisinin" post="from Artemisia annua against a model member of the"/>
</results>
